These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
427 related articles for article (PubMed ID: 32888648)
41. Combination efficacy of pertuzumab and trastuzumab for trastuzumab emtansine-resistant cells exhibiting attenuated lysosomal trafficking or efflux pumps upregulation. Yamashita-Kashima Y; Shu S; Osada M; Fujimura T; Yoshiura S; Harada N; Yoshimura Y Cancer Chemother Pharmacol; 2020 Nov; 86(5):641-654. PubMed ID: 32997196 [TBL] [Abstract][Full Text] [Related]
42. Molecular targeting of HER2-overexpressing biliary tract cancer cells with trastuzumab emtansine, an antibody-cytotoxic drug conjugate. Yamashita-Kashima Y; Yoshimura Y; Fujimura T; Shu S; Yanagisawa M; Yorozu K; Furugaki K; Higuchi R; Shoda J; Harada N Cancer Chemother Pharmacol; 2019 Apr; 83(4):659-671. PubMed ID: 30659304 [TBL] [Abstract][Full Text] [Related]
43. Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression. Li H; Takayama K; Wang S; Shiraishi Y; Gotanda K; Harada T; Furuyama K; Iwama E; Ieiri I; Okamoto I; Nakanishi Y Cancer Chemother Pharmacol; 2014 Dec; 74(6):1297-305. PubMed ID: 25344762 [TBL] [Abstract][Full Text] [Related]
44. PCC0208027, a novel tyrosine kinase inhibitor, inhibits tumor growth of NSCLC by targeting EGFR and HER2 aberrations. Dong Q; Yu P; Ye L; Zhang J; Wang H; Zou F; Tian J; Kurihara H Sci Rep; 2019 Apr; 9(1):5692. PubMed ID: 30952931 [TBL] [Abstract][Full Text] [Related]
45. Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation. Nakade J; Takeuchi S; Nakagawa T; Ishikawa D; Sano T; Nanjo S; Yamada T; Ebi H; Zhao L; Yasumoto K; Matsumoto K; Yonekura K; Yano S J Thorac Oncol; 2014 Jun; 9(6):775-83. PubMed ID: 24828661 [TBL] [Abstract][Full Text] [Related]
46. Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Faber AC; Li D; Song Y; Liang MC; Yeap BY; Bronson RT; Lifshits E; Chen Z; Maira SM; García-Echeverría C; Wong KK; Engelman JA Proc Natl Acad Sci U S A; 2009 Nov; 106(46):19503-8. PubMed ID: 19850869 [TBL] [Abstract][Full Text] [Related]
47. Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status. Formisano L; D'Amato V; Servetto A; Brillante S; Raimondo L; Di Mauro C; Marciano R; Orsini RC; Cosconati S; Randazzo A; Parsons SJ; Montuori N; Veneziani BM; De Placido S; Rosa R; Bianco R Oncotarget; 2015 Sep; 6(28):26090-103. PubMed ID: 26325669 [TBL] [Abstract][Full Text] [Related]
48. Enhanced anti-angiogenic effect of E7820 in combination with erlotinib in epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer xenograft models. Ito K; Semba T; Uenaka T; Wakabayashi T; Asada M; Funahashi Y Cancer Sci; 2014 Aug; 105(8):1023-31. PubMed ID: 24841832 [TBL] [Abstract][Full Text] [Related]
49. BEVERLY: Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Non-Small-Cell Lung Cancer. Gridelli C; Rossi A; Ciardiello F; De Marinis F; Crinò L; Morabito A; Morgillo F; Montanino A; Daniele G; Piccirillo MC; Normanno N; Gallo C; Perrone F Clin Lung Cancer; 2016 Sep; 17(5):461-465. PubMed ID: 27209164 [TBL] [Abstract][Full Text] [Related]
50. Phosphatase and tensin homolog deleted on chromosome 10 degradation induced by NEDD4 promotes acquired erlotinib resistance in non-small-cell lung cancer. Sun H; Ma H; Wang J; Xia L; Zhu G; Wang Z; Sun J; Chen Z Tumour Biol; 2017 Jul; 39(7):1010428317709639. PubMed ID: 28714370 [TBL] [Abstract][Full Text] [Related]
51. First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring an EGFR mutation. Landre T; Des Guetz G; Chouahnia K; Duchemann B; Assié JB; Chouaid C J Cancer Res Clin Oncol; 2020 Dec; 146(12):3333-3339. PubMed ID: 32632581 [TBL] [Abstract][Full Text] [Related]
52. Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer. Sato H; Yamamoto H; Sakaguchi M; Shien K; Tomida S; Shien T; Ikeda H; Hatono M; Torigoe H; Namba K; Yoshioka T; Kurihara E; Ogoshi Y; Takahashi Y; Soh J; Toyooka S Cancer Sci; 2018 Oct; 109(10):3183-3196. PubMed ID: 30098066 [TBL] [Abstract][Full Text] [Related]
53. Estrogen receptor β1 activation accelerates resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in non-small cell lung cancer. Fu S; Liu C; Huang Q; Fan S; Tang H; Fu X; Ai B; Liao Y; Chu Q Oncol Rep; 2018 Mar; 39(3):1313-1321. PubMed ID: 29328407 [TBL] [Abstract][Full Text] [Related]
54. Nicotine induces resistance to erlotinib via cross-talk between α 1 nAChR and EGFR in the non-small cell lung cancer xenograft model. Li H; Wang S; Takayama K; Harada T; Okamoto I; Iwama E; Fujii A; Ota K; Hidaka N; Kawano Y; Nakanishi Y Lung Cancer; 2015 Apr; 88(1):1-8. PubMed ID: 25670150 [TBL] [Abstract][Full Text] [Related]
55. EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer. Amato KR; Wang S; Tan L; Hastings AK; Song W; Lovly CM; Meador CB; Ye F; Lu P; Balko JM; Colvin DC; Cates JM; Pao W; Gray NS; Chen J Cancer Res; 2016 Jan; 76(2):305-18. PubMed ID: 26744526 [TBL] [Abstract][Full Text] [Related]
56. Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers. Peters S; Stahel R; Bubendorf L; Bonomi P; Villegas A; Kowalski DM; Baik CS; Isla D; Carpeno JC; Garrido P; Rittmeyer A; Tiseo M; Meyenberg C; de Haas S; Lam LH; Lu MW; Stinchcombe TE Clin Cancer Res; 2019 Jan; 25(1):64-72. PubMed ID: 30206164 [TBL] [Abstract][Full Text] [Related]
57. Hsp27 Inhibition with OGX-427 Sensitizes Non-Small Cell Lung Cancer Cells to Erlotinib and Chemotherapy. Lelj-Garolla B; Kumano M; Beraldi E; Nappi L; Rocchi P; Ionescu DN; Fazli L; Zoubeidi A; Gleave ME Mol Cancer Ther; 2015 May; 14(5):1107-16. PubMed ID: 25740245 [TBL] [Abstract][Full Text] [Related]
58. Trastuzumab emtansine for patients with non-small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations. Iwama E; Zenke Y; Sugawara S; Daga H; Morise M; Yanagitani N; Sakamoto T; Murakami H; Kishimoto J; Matsumoto S; Nakanishi Y; Goto K; Okamoto I Eur J Cancer; 2022 Feb; 162():99-106. PubMed ID: 34959152 [TBL] [Abstract][Full Text] [Related]
59. Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts. Iwai T; Moriya Y; Shirane M; Fujimoto-Ouchi K; Mori K Oncol Rep; 2012 Apr; 27(4):923-8. PubMed ID: 22209766 [TBL] [Abstract][Full Text] [Related]
60. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Gelatti ACZ; Drilon A; Santini FC Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]